(Total Views: 485)
Posted On: 09/16/2020 9:26:26 AM
Post# of 155036
The proposed compensation package is way too generous. NP's 7 figure base salary, plus
the options and CYDY stock he already has are already excessive. Thus far he is has not proven himself to be an effective CEO.
A small clinical stage OTC with no sales, no FDA approvals, that is in it's "prove it" phase should not rewarding an already overcompensated CEO and his suspect BOD.
the options and CYDY stock he already has are already excessive. Thus far he is has not proven himself to be an effective CEO.
A small clinical stage OTC with no sales, no FDA approvals, that is in it's "prove it" phase should not rewarding an already overcompensated CEO and his suspect BOD.
(10)
(0)
